At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with genetically defined diseases more collaborative, creative and productive.
Board of Directors
Mr. Clancy has served as a member of our board of directors since September 2013. Mr. Clancy has more than 30 years of experience in financial management and strategic business planning, and served as chief financial officer at Alexion Pharmaceuticals until December 2019. Prior to Alexion, he served as the executive vice president and chief financial officer at Biogen Inc. (formerly Biogen Idec) for 10 years. He also served as senior vice president of finance for Biogen Idec, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the merger of Biogen and Idec, Mr. Clancy was the vice president of portfolio management at Biogen Inc. He joined the company in 2001 as vice president of U.S. marketing.
Before Biogen Inc., Mr. Clancy spent 13 years at PepsiCo, serving in a variety of financial and general management positions, including vice president and general manager of their Great West Business Unit. Mr. Clancy is a member of the Board of Directors of Incyte Corporation. Mr. Clancy has an MBA from Columbia Business School in New York City and received his B.S. in business administration from Babson College in Wellesley, Mass.
Mr. Clark has served as a member of our board of directors since 2017. Mr. Clark served as the chief executive officer and member of the board of directors at Genentech, until his retirement in 2016. Prior to his role of chief executive officer, Mr. Clark held executive management roles at Genentech, including head of global product strategy, chief marketing officer, senior vice president, general manager of biooncology and executive vice president for commercial operations. Prior to these roles, Mr. Clark served as general manager, Novartis Canada and chief operating officer for Novartis U.K.
Before joining Novartis, Mr. Clark served in positions of increasing strategic importance in sales, marketing and business development at Ivax Pharma and Sanofi in the United Kingdom, France and Eastern Europe. He started his career at Searle (a subsidiary of Monsanto Corporation), holding positions in both sales and marketing. Mr. Clark serves as a member of the board of directors at Takeda, Guardant Health, Forty Seven, Avrobio and Corvus Pharmaceuticals. He is also on the BioFulcrum board of the Gladstone Institute. Mr. Clark received his B.S. in biological sciences and an honorary doctorate of science from Southampton University in the United Kingdom.
Ms. Foster has served as a member of our board of directors since December 2014. Ms. Foster has more than 25 years of experience in human resources in the pharmaceutical industry and is the former senior vice president, global human resources at Onyx Pharmaceuticals, Inc., an Amgen subsidiary. At Onyx, which was acquired by Amgen in 2013, she led all aspects of human resources for U.S. and global operations. Prior to joining Onyx, Ms. Foster was global vice president of human resources and an executive committee member at Johnson and Johnson from 2003 to 2010. Before Johnson and Johnson, Ms. Foster held several senior human resources executive positions with Pfizer Inc. supporting its pharmaceuticals businesses in Japan, Asia, Africa, Middle East and Latin America and, notably, led the integration of both the Warner-Lambert and Pharmacia mergers for these regions. Prior to that, she gained 10 years of operational experience within The Yellow Pages. She currently serves on the board of directors of Stanford Health Care, a hospital and healthcare system, and also serves on the boards of Spelman College, Glide Memorial Church and Girls for a Change. Ms. Foster is also very active in her community and has received several awards for her work. She earned her undergraduate degree at Baruch College of the City University of New York and received her MBA from Columbia University, Graduate School of Business.
Jackie Fouse, Ph.D.
Dr. Fouse has served as a member of our board of directors since December 2017 and became chief executive officer of Agios in February 2019. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. Fouse joined Celgene in 2010 as chief financial officer and was named president of the company’s global hematology & oncology franchise in 2014. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as senior vice president, chief financial officer, and head of corporate strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies, spending almost a decade of her career in Switzerland. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.
Maykin Ho, Ph.D.
Dr. Ho was appointed as an independent director to our board in June 2015. Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking. Previously, Dr. Ho held various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company. She is a member of the board of directors and chair of the audit committee for the Aaron Diamond AIDS Research Center in New York. She serves on the board of directors of PAREXEL International, a publicly-traded multinational life sciences consulting firm. She also served on the investment committee of the Society of Neuroscience. Dr. Ho was a postdoctoral fellow at the pathology department of Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. She received a Ph.D. in microbiology and immunology and a B.S. from the State University of New York, Downstate Medical Center.
John Maraganore, Ph.D.
Dr. Maraganore has served as a member of our board of directors since November 2011 and has served as lead independent director since February 2019. Since December 2002, Dr. Maraganore has served as the chief executive officer and as a director of Alnylam Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. From December 2002 to December 2007, Dr. Maraganore served as president of Alnylam. From April 2000 to December 2002, Dr. Maraganore served as senior vice president, strategic product development with Millennium. Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. (now Biogen Idec, Inc.), a publicly traded company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc. and The Upjohn Company. Dr. Maraganore is also a director of bluebird bio, Inc. and Tempero Pharmaceuticals. He is also a member of the Immunology Advisory Council of Harvard Medical School and a member of the board of directors of the Biotechnology Industry Organization. In addition, he was formerly a venture partner at Third Rock Ventures, L.P., and was formerly chairman of the board of directors of Regulus Therapeutics, Inc., a publicly traded company. Dr. Maraganore holds an M.S. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago and a B.A. in Biological Sciences from the University of Chicago.
David Scadden, M.D.
Dr. Scadden has served as a member of our board of directors since June 2017. Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute and is chairman and professor of the Harvard University Department of Stem Cell and Regenerative Biology. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function. Dr. Scadden is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund, and the Leukemia and Lymphoma Society. He has served or serves on the board of scientific counselors for the National Cancer Institute, the board of external experts for the National Heart, Lung and Blood Institute, board of directors of the International Society for Stem Cell Research (ISSCR), and is an associate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial and scientific advisory boards and is a scientific founder of Fate Therapeutics and Magenta Therapeutics, respectively a public and a private biotechnology company.
David Schenkein, M.D.
Dr. Schenkein joined Agios in August 2009 and served as president and chief executive officer until February 2019. He has also served as a member of our board of directors since August 2009, as our executive chair from February 2019 to February 2020, and as the chair of our board of directors since February 2020. He now serves as a general partner for life sciences at Google Ventures. He has been a hematologist and medical oncologist for more than 20 years and currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, from March 2006 to July 2009, Dr. Schenkein was the senior vice president, clinical hematology/oncology, at Genentech, Inc., a pharmaceutical company, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. While at Genentech, he served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceuticals Company Limited), overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. In addition to Agios, he currently serves on the board of directors of Denali Therapeutics, Inc. Dr. Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.
Lewis C. Cantley, Ph.D.
The Cancer Center at Weill Cornell Medical College
and New York-Presbyterian Hospital
Ralph Deberardinis, M.D., Ph.D.
Children’s Medical Center Research Institute at UT Southwestern
Tak Mak, Ph.D.
University of Toronto and the Campbell Family Institute for Breast Cancer Research
Shin-San Michael Su, Ph.D.
Former SVP of Research and Development at Agios
Marc Tessier-Lavigne, Ph.D.
Craig B. Thompson, M.D.
Chair of the scientific advisory board, Memorial Sloan-Kettering Cancer Center
Matthew Vander Heiden, M.D., Ph.D.
Koch Institute for Integrative Cancer Research at MIT
Scott Biller, Ph.D.
Former Chief Scientific Officer at Agios
Lewis C. Cantley, Ph.D.
Director of the Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital
Dr. Cantley is a foremost expert in understanding the biochemical pathways linking cancer and energy metabolism. His key contributions include:
- Discovering the phosphatidylinositol-3-kinase (PI3K) signaling pathway
- Characterizing the mechanism by which PI3K is activated by growth factors and oncogenes and elucidating pathways downstream of PI3K, including the AKT/PKB signaling pathway
- Pioneering the application of fluorescence resonance energy transfer (FRET) for studying small molecule cell membrane transport
- Discovering pyruvate kinase M2 (PKM2) as a “hub” to integrate growth factor signaling and aerobic glycolysis, an evolution in the understanding of the Warburg effect.
Tak Mak, Ph.D.
Professor, University of Toronto; Director of the Advanced Medical Discovery Institute; Director of the Campbell Family Institute for Breast Cancer Research
Dr. Mak is a preeminent researcher of the biology of the immune system, the biology of apoptosis and the pathogenesis of cancer. His key contributions include:
- Discovering the T-Cell receptor
- Characterizing the tumorigenic functions of the tumor suppressor protein p53 and the kinase Chk2
- Identifying CPT1C as a tumor-specific gene product that plays an important role in the utilization of fatty acids as an alternative energy source of cancer cells
- Discovery of the function of CTLA-4
Shin-San Michael Su, Ph.D.
Chief Scientific Officer at Decibel Therapeutics
Dr. Su was one of Agios’ founding scientists and its first employee. He served as senior vice president, research & development from 2012-2016. Dr. Su has more than 20 years of organization, project management and scientific experience in the biotechnology industry. Prior to Agios, from 2004 to 2006, he served as general director and vice president of the Biomedical Engineering Research Laboratory (BEL) at ITRI in Taiwan. Prior to that, he spent 14 years in a number of roles, concluding his tenure as program executive and vice president of the Novartis kinase collaboration for Vertex Pharmaceuticals, a publicly traded pharmaceutical company. Dr. Su earned his Ph.D. in biochemistry at Duke University and was a Helen Hay Whitney Fellow at Harvard University.
Craig B. Thompson, M.D.
President and CEO of Memorial Sloan-Kettering Cancer Center
Dr. Thompson is an authority in the study of how genes regulate apoptosis and metabolism and investigates their application in treating cancer. His key contributions include:
- Elucidating the role of the Bcl-2 family of oncogenes role in regulating cell survival
- Identifying the roles of aerobic glycolysis, fatty acid synthesis and autophagy in the metabolic adaptation by cancer cells as part of carcinogenesis
- Proposing the concept that most oncogenes and tumor suppressors evolved to regulate cellular metabolism
CEO of Agios
Whether it’s virtual or in person, we’re better when we’re together. Strong personal connections between our mission, the science and each other are what fuels us to move further and faster for patients.
Join our team
Explore our open positions!